Optimizing anti-inflammatory reliever therapy- A fundamental change in approach to treating asthma

(CEM 258 EN) 

Format: Conference

Duration: 1 hour of recognized professional development activity

Start date: May 2022

Validation and credit: 1 hour of recognized professional development activity

Learning objectives

Upon completion of this module, participants will be better able to:

  • Discuss recent evidence on anti-inflammatory reliever therapy in reducing asthma exacerbations
  • Discuss why over-reliance on short-acting beta-agonists (SABA) increases the risk of exacerbations and worsening of asthma
  • Describe the latest asthma treatment recommendations from the Canadian Thoracic Society (CTS; 2021) and the Global Initiative for Asthma (GINA; 2021)
  • Review asthma management in patients with asthma and COVID-19

Planning Committee:

    • Jacques Bouchard, MD, CCFP
    • Isabel Coman, MD, FRCPC
    • John Axler, MD, CCFP, FCMF

Collaboration: This training program was supported by an educational grant from AstraZeneca

Organisation médicale: International Centre for Evidence-Based Medicine Canada

Renseignements: Direction de la Formation professionnelle de la FMOQ. 514 878-1911 ou au 1 800 361-8499, dfp@fmoq.org